

Differential Gene Expression Caused by Cisplatin in Ovarian Cancer Cell Lines

Maya Jones, Hong Qin

Spelman College, Department of Biology, Atlanta, GA 30314



ABSTRACT

Ovarian cancers often become resistant to cisplatin, a chemotherapy drug. It has been hypothesized that the epithelialmesenchymal transition(EMT) contributes to the resistance of cisplatin in cancer cells. The EMT is a physiological process that is involved in cancer cell invasion and metastasis. When cells lose their epithelial characteristics and gain mesenchymal properties, it is believed that this causes invasion and metastasis. Thus, we compared an epithelial ovarian cancer cell line OVCA 420 and a mesenchymal cancer cell line OV90, to determine which biological processes and cellular components showed differences in gene expression.

BACKGROUND

Cisplatin is an anti-cancer chemotherapy drug that works by stopping the cancer cells from multiplying. It binds together the strands of the cells' genetic material, DNA. Cisplatin damages the DNA inside the cancer cells and so prevents them from multiplying. Ovarian cancer is a type of cancer that begins in the ovaries and forms tumors in the cells covering the ovaries.

MATERIALS

DATA SOURCE:

NCBI (National Center for Biotechnology Information) After extracting the data from NCBI, two particular cell lines were selected for comparison. These selected cell lines included both treated and untreated cisplatin cells.

OVCA 420-epithelial OV90-mesenchymal

cl	naracteristics_	ch1 characteristics_ch1.2	
GSM1160772	cell line: 0	790 treatment: none	
GSM1160773	cell line: 0	790 treatment: none	
GSM1160774	cell line: 0	790 treatment: none	
GSM1160775	cell line: 0	790 treatment: Cisplatin	
GSM1160776	cell line: 0	790 treatment: Cisplatin	
GSM1160777	cell line: 0	790 treatment: Cisplatin	

METHODS

R limma package


Performs analysis of expression profiles in terms of co-regulated sets of genes or in terms of higher-order expression signatures, which provides enhanced possibilities for biological interpretation of gene expression differences between the cancer cell lines


Pathway Analysis
Identifies specific
differences contributing
to the resistance of
particular cancer cells
versus others


Network Clustering Analysis

This type of analysis measures the similarity of genes and their expression patterns. These measures of similarity can be measured in various ways that are problem dependent, for example, by the correlation coefficient between the selected genes.

RESULTS







CONCLUSION

We found that cisplatin significantly up-regulated cell cycle pathways in the epithelial-like cancer cell line of OVCA 420. On the contrast, cisplatin significantly down-regulated cell cycle pathways in mesenchymal-like cancer cell line of OV90. Our results suggest that mesenchymal-like cancer cells are more resistant to cisplatin by down-regulation through its cell proliferation process. This research is the beginning for identifying which part in the cell cycle is affecting patients' resistance to chemotherapy treatments. In the future this research will be transferred to actual treated and untreated cells versus untreated and treated cell lines.

REFERENCES

Kalluri, Raghu, and Robert A. Weinberg. "The Basics of Epithelial-mesenchymal Transition." *JCI - The Basics of Epithelial-mesenchymal Transition*. The Journal of Clinical Investigation, June 2009. Web. 04 Feb. 2016.

Katabuchi, H. "Cell Biology of Human Ovarian Surface Epithelial Cells and Ovarian Carcinogenesis." *National Center for Biotechnology Information*. U.S. National Library of Medicine, June 2003. Web. 04 Feb. 2016.

Sharan, R., R. Elkon, and R. Shamir. "Correction: Cluster Analysis and Display of Genome-Wide Expression Patterns." *Proceedings of the National Academy of Sciences of the United States of America* 96.19 (1999): 10943. Department of Human Genetics and Molecular Medicine. Web.

QH Miow TZ Tan J Ye, JA Lau, T Yokomizo, J-P Thiery and S Mori. Epithelial–mesenchymal status renders differential responses to cisplatin in ovarian cancer.

ACKNOWLEDGEMENTS

This research was partially supported by Spelman College Research Initiative for Scientific Enhancement (RISE; Grant #2R5GM06566-13). Research was conducted in the Biology Department at Spelman College under Dr. Hong Qin. Special thanks to Spelman College RISE program.